Sarepta Therapeutics, Inc. — Form 10-Q Summary
Reporting period: Three and nine months ended September 30, 2023; filed November 1, 2023. Sarepta is a commercial-stage biopharmaceutical company focused on RNA-targeted therapeutics, gene therapy and other genetic medicines for rare diseases, particularly Duchenne muscular dystrophy.
Business Context and Reporting Period
- The FDA granted accelerated approval to ELEVIDYS in June 2023, Sarepta’s fourth approved product and its first gene therapy. The product generated initial U.S. sales during the quarter.
- Existing commercial products are EXONDYS 51, VYONDYS 53 and AMONDYS 45. Sarepta also maintains a pipeline of more than 40 programs, including SRP-5051 and SRP-9003.
- The financial statements are unaudited and prepared under U.S. GAAP. Management states that current liquidity is sufficient to fund its operational plan for at least the next twelve months.
Financial Performance and Position
| Metric | Q3 2023 | Q3 2022 | 9M 2023 | 9M 2022 |
|---|---|---|---|---|
| Total revenue | $331.8 million | $230.3 million | $846.6 million | $674.6 million |
| Product revenue | $309.3 million | $207.8 million | $779.8 million | $607.8 million |
| Collaboration revenue | $22.5 million | $22.5 million | $66.8 million | $66.8 million |
| Operating loss | $(20.8) million | $(131.4) million | $(292.4) million | $(429.4) million |
| Net loss | $(40.9) million | $(257.7) million | $(581.6) million | $(594.2) million |
| Net loss per share | $(0.46) | $(2.94) | $(6.56) | $(6.79) |
| Cash used in operating activities | Not separately provided | Not separately provided | $(446.3) million | $(233.0) million |
- Q3 product revenue increased 49%, while total revenue increased 44%. Nine-month product revenue increased 28% and total revenue increased 25%.
- Q3 revenue included $69.1 million from ELEVIDYS. PMO product revenue was $240.2 million in Q3, including $198.1 million in the U.S. and $42.1 million internationally.
- Q3 cost of sales, including amortization of in-licensed rights, was approximately $37.5 million, implying an approximate gross margin of 88.7%. The nine-month gross margin was approximately 87.4%. These margins benefited from certain ELEVIDYS manufacturing costs being expensed as research and development before approval.
- Q3 operating margin was approximately negative 6.3%; the nine-month operating margin was approximately negative 34.6%.
- Research and development expense was $194.3 million in Q3 and $681.9 million for nine months. Selling, general and administrative expense was $120.9 million in Q3 and $350.2 million for nine months.
- Stock-based compensation was $48.1 million in Q3 and $136.7 million for nine months.
- Cash, cash equivalents, short-term investments and restricted cash totaled $1.753 billion at September 30, 2023, compared with $2.008 billion at December 31, 2022. Working capital was $2.000 billion.
- Long-term debt carrying value was $1.237 billion, compared with $1.544 billion at year-end 2022. Debt principal consisted primarily of $105.8 million of 2024 Notes and $1.150 billion of 2027 Notes.
- Total liabilities were $2.345 billion and stockholders’ equity was $764.4 million at September 30, 2023.
Material Changes Versus Prior Comparable Period
- ELEVIDYS added $69.1 million of product revenue in Q3 and the first nine months of 2023.
- PMO product revenue increased due to higher demand: nine-month EXONDYS 51 revenue rose 12%, AMONDYS 45 rose 33% and VYONDYS 53 rose 9%.
- Q3 operating loss improved by $110.5 million, primarily because of higher revenue and lower manufacturing and research and development costs. Nine-month operating loss improved by $136.9 million.
- Q3 net loss improved by $216.8 million, largely because the prior-year period included a $125.4 million debt extinguishment loss. The nine-month 2023 period included a larger, non-cash $387.3 million loss from exchanging $313.5 million of 2024 Notes for approximately 4.5 million common shares.
- Research and development expense declined 10% in Q3 but increased 3% for nine months. The Q3 decline primarily reflected lower manufacturing expenses, partly offset by higher clinical-trial, personnel and stock-based compensation costs.
- Operating cash outflow increased to $446.3 million from $233.0 million. Key uses included increases in accounts receivable and inventory, payments to suppliers and a decrease in deferred Roche revenue.
- In June 2023, Sarepta sold the ELEVIDYS Priority Review Voucher for $102.0 million, recognized as a gain.
- The company commenced the Bedford, Massachusetts lease in May 2023, recording a lease liability of $84.1 million and a right-of-use asset of $71.7 million at September 30, 2023.
Guidance, Outlook, Commentary and Risks
- No formal full-year revenue or earnings guidance is provided in the filing. Management expects to continue incurring significant operating losses at least through 2023.
- Management identified planned or anticipated milestones including initiating a potentially pivotal SRP-9003 trial by year-end 2023, announcing top-line results from Part B of Study 5051-201 by year-end 2023, and submitting a BLA supplement to expand the ELEVIDYS label.
- Management expects current liquidity to fund the current operational plan for at least twelve months, but may seek additional debt, equity, collaboration, licensing or government funding.
- Contractual obligations are significant: approximately $1.3 billion of debt obligations, $365.8 million of lease obligations and $1.5 billion of manufacturing commitments. Future contingent development, regulatory, commercial and royalty milestones under license and collaboration agreements could total up to $3.2 billion.
- ELEVIDYS and the other approved products have accelerated approvals and require confirmatory studies and other post-marketing commitments. Failure to verify clinical benefit or comply with regulatory requirements could lead to labeling changes, restrictions or withdrawal of approval.
- Material risks include reliance on U.S. product sales, reimbursement and payer coverage, competition, manufacturing concentration and supply constraints, adverse clinical or regulatory outcomes, intellectual-property litigation, and continued operating cash burn.
- Regenxbio and the University of Pennsylvania have two patent infringement lawsuits concerning ELEVIDYS manufacturing and commercialization. Trials were scheduled for January 2024 and November 2025; management has not recorded a material loss contingency and states that no material loss range is estimable.
- A separate Nippon Shinyaku patent and contract dispute remains active, with a U.S. trial scheduled for May 2024 and a Japanese proceeding scheduled for July 2024.
Most Important Facts for Investors to Verify
- ELEVIDYS demand, net pricing, payer coverage, manufacturing capacity and potential cannibalization of PMO product sales.
- Progress and outcomes of ELEVIDYS confirmatory and label-expansion studies, including regulatory requirements associated with accelerated approval.
- Cash burn, investment balances, debt maturities, refinancing needs and the company’s stated twelve-month liquidity assessment.
- Manufacturing commitments, supply qualification, inventory levels and potential inventory write-offs.
- Status and potential financial impact of Regenxbio/University of Pennsylvania and Nippon Shinyaku litigation.
- Clinical and regulatory milestones for SRP-5051, SRP-9003 and other pipeline programs, together with related spending and contingent payments.
- Revenue concentration: three customers represented 40%, 23% and 9% of Q3 product revenue, and 45%, 29% and 8% of nine-month product revenue.